These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37476372)

  • 1. Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.
    Langberg CW; Horndalsveen H; Helland Å; Haakensen VD
    Front Oncol; 2023; 13():1217424. PubMed ID: 37476372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
    Tanzawa S; Ushijima S; Shibata K; Shibayama T; Bessho A; Kaira K; Misumi T; Shiraishi K; Matsutani N; Tanaka H; Inaba M; Haruyama T; Nakamura J; Kishikawa T; Nakashima M; Iwasa K; Fujiwara K; Kohyama T; Kuyama S; Miyazawa N; Nakamura T; Miyawaki H; Ishida H; Oda N; Ishikawa N; Morinaga R; Kusaka K; Fujimoto N; Yokoyama T; Gemba K; Tsuda T; Nakagawa H; Ono H; Shimizu T; Nakamura M; Kusumoto S; Hayashi R; Shirasaki H; Ochi N; Aoe K; Kanaji N; Kashiwabara K; Inoue H; Seki N
    Ther Adv Med Oncol; 2021; 13():1758835921998588. PubMed ID: 33717228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
    Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
    Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
    Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
    Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
    Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
    Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
    Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
    Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
    Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
    Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
    Avrillon V; Daniel C; Boisselier P; Le Péchoux C; Chouaid C
    Lung; 2022 Feb; 200(1):95-105. PubMed ID: 35141799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.
    Wass R; Hochmair M; Kaiser B; Grambozov B; Feurstein P; Weiß G; Moosbrugger R; Sedlmayer F; Lamprecht B; Studnicka M; Zehentmayr F
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
    Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
    Guggenberger J; Kenndoff S; Taugner J; Käsmann L; Flörsch B; Belka C; Eze C; Manapov F
    BMC Cancer; 2022 Mar; 22(1):317. PubMed ID: 35331196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
    Liu J; Bratton E; Yu X; Ladbury C; Wagner J; West H; Massarelli E; Salgia R; Pathak R; Villaflor V; Villalona-Calero M; Amini A
    Am J Clin Oncol; 2022 Feb; 45(2):49-54. PubMed ID: 34991107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.